Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8581 |
High Similarity |
NPD5761 |
Phase 2 |
0.8581 |
High Similarity |
NPD5760 |
Phase 2 |
0.8118 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7914 |
Intermediate Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.7758 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7669 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7625 |
Intermediate Similarity |
NPD920 |
Approved |
0.75 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7425 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7375 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7349 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7325 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7321 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7314 |
Intermediate Similarity |
NPD6765 |
Approved |
0.7314 |
Intermediate Similarity |
NPD6764 |
Approved |
0.7314 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7305 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7284 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.725 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7241 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7193 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7188 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7178 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7178 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7178 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7176 |
Intermediate Similarity |
NPD919 |
Approved |
0.717 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.717 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6784 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6785 |
Approved |
0.7151 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7108 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7101 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7093 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7086 |
Intermediate Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7069 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7066 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7041 |
Intermediate Similarity |
NPD8404 |
Phase 2 |
0.7041 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7039 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7029 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7019 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7018 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7012 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7006 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6975 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.697 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.697 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6949 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6937 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6933 |
Remote Similarity |
NPD3750 |
Approved |
0.6914 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.691 |
Remote Similarity |
NPD7074 |
Phase 3 |
0.6894 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6893 |
Remote Similarity |
NPD3818 |
Discontinued |
0.6886 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6886 |
Remote Similarity |
NPD5403 |
Approved |
0.6882 |
Remote Similarity |
NPD1934 |
Approved |
0.6879 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD6166 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD2800 |
Approved |
0.6867 |
Remote Similarity |
NPD5401 |
Approved |
0.6857 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6855 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6854 |
Remote Similarity |
NPD7054 |
Approved |
0.6848 |
Remote Similarity |
NPD7236 |
Approved |
0.6842 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD8032 |
Phase 2 |
0.6832 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6831 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6821 |
Remote Similarity |
NPD17 |
Approved |
0.6816 |
Remote Similarity |
NPD7472 |
Approved |
0.6805 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6798 |
Remote Similarity |
NPD7228 |
Approved |
0.6796 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD4307 |
Phase 2 |
0.6784 |
Remote Similarity |
NPD37 |
Approved |
0.6778 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6771 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6763 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6763 |
Remote Similarity |
NPD3882 |
Suspended |
0.6763 |
Remote Similarity |
NPD4966 |
Approved |
0.6763 |
Remote Similarity |
NPD4965 |
Approved |
0.6761 |
Remote Similarity |
NPD5711 |
Approved |
0.6761 |
Remote Similarity |
NPD6808 |
Phase 2 |
0.6761 |
Remote Similarity |
NPD5710 |
Approved |
0.6748 |
Remote Similarity |
NPD2344 |
Approved |
0.6746 |
Remote Similarity |
NPD7239 |
Suspended |
0.6744 |
Remote Similarity |
NPD2801 |
Approved |
0.674 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6737 |
Remote Similarity |
NPD8285 |
Discontinued |
0.6732 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6728 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6727 |
Remote Similarity |
NPD7003 |
Approved |
0.6726 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6704 |
Remote Similarity |
NPD7799 |
Discontinued |
0.6704 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6703 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6688 |
Remote Similarity |
NPD3972 |
Approved |
0.6688 |
Remote Similarity |
NPD1608 |
Approved |
0.6686 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6685 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6684 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6684 |
Remote Similarity |
NPD7697 |
Approved |
0.6684 |
Remote Similarity |
NPD7497 |
Discontinued |
0.6684 |
Remote Similarity |
NPD7698 |
Approved |
0.6667 |
Remote Similarity |
NPD3764 |
Approved |
0.6667 |
Remote Similarity |
NPD3266 |
Approved |
0.6667 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6667 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD3267 |
Approved |
0.6667 |
Remote Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.6648 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6648 |
Remote Similarity |
NPD7240 |
Approved |
0.6647 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6646 |
Remote Similarity |
NPD1933 |
Approved |
0.663 |
Remote Similarity |
NPD8407 |
Phase 2 |
0.6628 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6626 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6624 |
Remote Similarity |
NPD1019 |
Discontinued |
0.6616 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6616 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6615 |
Remote Similarity |
NPD6778 |
Approved |
0.6615 |
Remote Similarity |
NPD6780 |
Approved |
0.6615 |
Remote Similarity |
NPD6776 |
Approved |
0.6615 |
Remote Similarity |
NPD6782 |
Approved |
0.6615 |
Remote Similarity |
NPD6777 |
Approved |
0.6615 |
Remote Similarity |
NPD6781 |
Approved |
0.6615 |
Remote Similarity |
NPD4107 |
Approved |
0.6615 |
Remote Similarity |
NPD6779 |
Approved |
0.661 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6609 |
Remote Similarity |
NPD5353 |
Approved |
0.6609 |
Remote Similarity |
NPD5616 |
Clinical (unspecified phase) |
0.6605 |
Remote Similarity |
NPD1607 |
Approved |
0.6593 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6587 |
Remote Similarity |
NPD2309 |
Approved |
0.6585 |
Remote Similarity |
NPD2438 |
Suspended |
0.6584 |
Remote Similarity |
NPD2979 |
Phase 3 |
0.6584 |
Remote Similarity |
NPD1240 |
Approved |
0.6578 |
Remote Similarity |
NPD4287 |
Approved |
0.6575 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6569 |
Remote Similarity |
NPD7907 |
Approved |
0.6566 |
Remote Similarity |
NPD7874 |
Approved |
0.6566 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6564 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6564 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6562 |
Remote Similarity |
NPD3268 |
Approved |
0.6561 |
Remote Similarity |
NPD2797 |
Approved |
0.6557 |
Remote Similarity |
NPD8368 |
Discontinued |
0.6548 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6545 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6545 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6545 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6545 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6545 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6543 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6543 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6543 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD5585 |
Approved |
0.6532 |
Remote Similarity |
NPD5890 |
Approved |
0.6532 |
Remote Similarity |
NPD5889 |
Approved |
0.6527 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6519 |
Remote Similarity |
NPD7177 |
Discontinued |
0.6519 |
Remote Similarity |
NPD2798 |
Approved |
0.6509 |
Remote Similarity |
NPD1511 |
Approved |
0.6503 |
Remote Similarity |
NPD6651 |
Approved |
0.65 |
Remote Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.6495 |
Remote Similarity |
NPD4482 |
Phase 3 |
0.6494 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6494 |
Remote Similarity |
NPD6279 |
Approved |
0.6494 |
Remote Similarity |
NPD3412 |
Clinical (unspecified phase) |
0.6494 |
Remote Similarity |
NPD6280 |
Approved |
0.6488 |
Remote Similarity |
NPD3887 |
Approved |
0.6481
|
Remote Similarity |
NPD4140 |
Approved |